MET alterations in primary tumors commonly entail missense mutations or exon 14 skipping mutations, whereas in colorectal and NSCLC patients, MET amplification has been identified as a mechanism of acquired resistance following treatment with EGFR tyrosine kinase inhibitors [24,25]. The gene discussed is MET; the disease is non-small cell lung carcinoma.